News on NeoGenisis Drug Discovery Incorporated from BioPortfolio.com http://www.BioPortfolio.com Consolidated NeoGenisis Drug Discovery Incorporated news from BioPortfolio.com Tue, 09 Feb 2010 22:49:15 GMT en Genta commences Phase 2 trial of tesetaxel on first subjecthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034650&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034650&THISHREF=http://c.moreover.com/click/here.pl%3fz2535909558%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034650&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034650&THISHREF=http://c.moreover.com/click/here.pl%3fz2535909558%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Genta commences treatment in tesetaxel Phase 2 trial for advanced melanomahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033220&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033220&THISHREF=http://c.moreover.com/click/here.pl%3fz2535076243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033220&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033220&THISHREF=http://c.moreover.com/click/here.pl%3fz2535076243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Drug Discovery In India and China Gaining Momentum with Increasing Pressure on Cost Cuttinghttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034581&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034581&THISHREF=http://c.moreover.com/click/here.pl%3fz2535872288%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034581&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034581&THISHREF=http://c.moreover.com/click/here.pl%3fz2535872288%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYour Story: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinsons disease biomarkerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Dishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinsons Diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032548&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032548&THISHREF=http://c.moreover.com/click/here.pl%3fz2534701440%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032548&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032548&THISHREF=http://c.moreover.com/click/here.pl%3fz2534701440%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037637&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037637&THISHREF=http://c.moreover.com/click/here.pl%3fz2537198799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037637&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037637&THISHREF=http://c.moreover.com/click/here.pl%3fz2537198799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: First call for targets from MRC Centre for Therapeutics Discoveryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035196&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035196&THISHREF=http://c.moreover.com/click/here.pl%3fz2536156074%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035196&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035196&THISHREF=http://c.moreover.com/click/here.pl%3fz2536156074%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Times: CRT, AstraZeneca announce alliance to develop new anti-cancer drugshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033316&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033316&THISHREF=http://c.moreover.com/click/here.pl%3fz2535122849%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033316&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033316&THISHREF=http://c.moreover.com/click/here.pl%3fz2535122849%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Research and Markets: The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032204&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032204&THISHREF=http://c.moreover.com/click/here.pl%3fz2534544615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032204&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032204&THISHREF=http://c.moreover.com/click/here.pl%3fz2534544615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Devhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037915&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037915&THISHREF=http://c.moreover.com/click/here.pl%3fz2537371102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037915&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037915&THISHREF=http://c.moreover.com/click/here.pl%3fz2537371102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037876&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037876&THISHREF=http://c.moreover.com/click/here.pl%3fz2537348639%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037876&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=NeoGenisis%20Drug%20Discovery%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037876&THISHREF=http://c.moreover.com/click/here.pl%3fz2537348639%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinanzNachrichten.de: